Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study
Felice Giuliante(Università Cattolica del Sacro Cuore), Giuseppe Zimmitti(Fondazione Poliambulanza Istituto Ospedaliero), Nadia Russolillo, Enrico Gringeri(University of Padua), Umberto Cillo(University of Padua), Andrea Ruzzenente(University of Verona), Alessandro Ferrero, Matteo Cescon(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Marco Massani(AULSS 2 Marca Trevigiana), Francesca Ratti(Vita-Salute San Raffaele University), Luciano De Carlis(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Matteo Zanello(Ospedale Maggiore), Marco Colasanti(University of Palermo), Salvatore Gruttadauria, Antonio Daniele Pinna(Cleveland Clinic), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Nazario Portolani(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Carlo Sposito(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Ardito(Agostino Gemelli University Polyclinic), Alfredo Guglielmi(University of Verona), Giuseppe Maria Ettorre(Carlo Forlanini Hospital), Elio Jovine(Azienda USL di Bologna), Stefano Di Sandro, Edoardo Rosso(Fondazione Poliambulanza Istituto Ospedaliero), Luca Aldrighetti(Vita-Salute San Raffaele University)
Cited by 26
Related Papers
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821